Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.34 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.34 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376553 | 0.87 | SLC2A1 (0.36) | SLC2A1BCHETRPC3TRPC4TRPC5 | |
| SCHEMBL6034488 | 0.87 | SLC2A1 (0.36) | SLC2A1BCHETRPC3TRPC4TRPC5 | |
| SCHEMBL6034804 | 0.87 | SLC2A1 (0.36) | SLC2A1BCHETRPC3TRPC4TRPC5 | |
| SCHEMBL5384788 | 0.87 | SLC2A1 (0.36) | SLC2A1BCHETRPC3TRPC4TRPC5 | |
| Hydrochloric Acid SCHEMBL5373961 | 0.86 | SLC2A1 (0.35) | SLC2A1BCHETRPC3TRPC4TRPC5 | |
| Hydrochloric Acid SCHEMBL5379165 | 0.86 | SLC2A1 (0.35) | SLC2A1BCHETRPC3TRPC4TRPC5 | |
| SCHEMBL5379452 | 0.82 | SLC2A1 (0.41) | SLC2A1BCHETRPC3TRPC4TRPC5 | |
| SCHEMBL5381623 | 0.78 | SLC2A1 (0.51) | SLC2A1BCHETRPC3TRPC4TRPC5 | |
| Hydrochloric Acid SCHEMBL5373989 | 0.78 | SLC2A1 (0.38) | SLC2A1BCHETRPC3TRPC4TRPC5 | |
| SCHEMBL5379063 | 0.77 | BCHE (0.33) | SLC2A1BCHETRPC3TRPC4TRPC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213362-A1 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | REPLIDYNE, INC. (US) | 2007-09-13 | — | — | US | claimed |
| US-7220757-B2 | Compositions and methods for topical administration of 2-NH-heteroarylimidazoles | REPLIDYNE, INC. (US) | 2007-05-22 | — | — | US | claimed |
| US-20060014748-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | BERGE JOHN | 2006-01-19 | — | — | US | claimed |
| EP-1581220-A2 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | Replidyne, Inc. (US) | 2005-10-05 | — | — | EP | claimed |
| US-6943175-B2 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. (US) | 2005-09-13 | — | — | US | claimed |
| US-20040147548-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. | 2004-07-29 | — | — | US | claimed |
| WO-2004052288-A2 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | REPLIDYNE, INC. (US) | 2004-06-24 | — | — | WO | claimed |
| US-20070213362-A1 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | REPLIDYNE, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-7220757-B2 | Compositions and methods for topical administration of 2-NH-heteroarylimidazoles | REPLIDYNE, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060128735-A1 | Substituted thiophenes with antibacterial activity | REPLIDYNE, INC. (US) | 2006-06-15 | — | — | US | disclosed |
| US-7030137-B2 | Substituted thiophenes with antibacterial activity | REPLIDYNE, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060014748-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | BERGE JOHN | 2006-01-19 | — | — | US | disclosed |
| US-6943175-B2 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| US-20050009833-A1 | Substituted thiophenes with antibacterial activity | REPLIDYNE, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040147548-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147548-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | NSUN3, TRMT1, NOP2 | SLC2A1 3689/4885BCHE 2921/4885TRPC3 3042/4885 |
| US-20050009833-A1 | Substituted thiophenes with antibacterial activity | TST, MTR, NSUN3 | SLC2A1 2761/4885BCHE 1197/4885TRPC3 3505/4885 |
| US-20060128735-A1 | Substituted thiophenes with antibacterial activity | TST, MTR, NSUN3 | SLC2A1 2761/4885BCHE 1197/4885TRPC3 3505/4885 |
| US-20070213362-A1 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | MET, ASNS, MRPS22 | SLC2A1 2998/4885BCHE 1927/4885TRPC3 4800/4885 |
| US-20060014748-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | TRMT1, NSUN3, NOP2 | SLC2A1 3868/4885BCHE 2752/4885TRPC3 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.